Refine
Has Fulltext
- yes (74)
Is part of the Bibliography
- yes (74)
Year of publication
Document Type
- Journal article (74) (remove)
Language
- English (74)
Keywords
- PET (19)
- Positronen-Emissions-Tomografie (14)
- positron emission tomography (12)
- theranostics (11)
- CXCR4 (9)
- multiple myeloma (9)
- PET/CT (8)
- PRRT (8)
- neuroendocrine tumor (7)
- molecular imaging (5)
- PSMA (4)
- SPECT (4)
- SSTR (4)
- prostate cancer (4)
- somatostatin receptor (4)
- 18F-FDG (3)
- FDG (3)
- NET (3)
- RADS (3)
- chemokine receptor (3)
- medicine (3)
- norepinephrine transporter (3)
- peptide receptor radionuclide therapy (3)
- radioligand therapy (3)
- sympathetic nervous system (3)
- 18F-FDG PET/CT (2)
- 18F-FDS (2)
- 18F-LMI1195 (2)
- DOTATOC (2)
- MAG3 (2)
- Positron emission tomography (2)
- Prostate Cancer (2)
- antidepressant (2)
- bone disease (2)
- diabetes (2)
- fibroblast activation protein (2)
- glioblastoma multiforme (2)
- heart failure (2)
- kidney (2)
- medullary thyroid carcinoma (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- radionuclide therapy (2)
- relapse (2)
- sarcoidosis (2)
- survival (2)
- tyrosine kinase inhibitor (2)
- vandetanib (2)
- 11C-HED (1)
- 11C-Hydroxyephedrine (1)
- 11C-Methionine PET/CT (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 18F-DCFPyL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 53BP1 (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Antibodies (1)
- Antidepressants (1)
- Arginine (1)
- BRAF mutation (1)
- C-11-methionine pet (1)
- C-X-C motif chemokine receptor 4 (1)
- CD38 (1)
- CXCR4/SDF-1 (1)
- Capicua transcriptional repressor (1)
- Cardiovascular diseases (1)
- DNA double-strand breaks (1)
- DOTA-EB-TATE (1)
- DaTscan (1)
- Drug resistance (1)
- ECG (1)
- Extramedullary disease (1)
- F-18-FDG PET (1)
- FDG PET/CT (1)
- GI (1)
- Ga-68 (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Heart failure (1)
- Hyperkalaemia (1)
- Imaging pitfalls (1)
- Lysine (1)
- MDD (1)
- MIBG (1)
- MIBG scintigraphy (1)
- MOR202 (1)
- MPI (1)
- MRI (1)
- Medullärer Schilddrüsenkrebs (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- Myocardial-perfusion SPECT (1)
- Myokarditis (1)
- NEC (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PSMA-PET (1)
- Parkinson's disease (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pentixafor (1)
- Pitfall (1)
- Positron Emission Tomography (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- Radiofluorine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- SUV (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Somatostatin receptor expression (1)
- Stammzelle (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TKI (1)
- Tracer (1)
- Virchow Node (1)
- ZDF rats (1)
- [177Lu]-DOTATATE/-DOTATOC (1)
- [177Lu]/[90Y]PentixaTher (1)
- [68Ga] (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- \(^{68}\)Ga-Pentixafor (1)
- accuracy (1)
- ageing (1)
- agreement (1)
- amino acids (1)
- androgen deprivation therapy (1)
- angiogenesis (1)
- autologous transplantation (1)
- benzylguanidine (1)
- biokinetics (1)
- biomarker (1)
- biomarkers (1)
- biosynthesis (1)
- bone marrow cells (1)
- brain (1)
- brain tumors (1)
- cancer (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardiomyocytes (1)
- cell staining (1)
- cells (1)
- cerebral gliomas (1)
- chemokine receptor-4 (1)
- clinical diagnosis (1)
- collimator (1)
- comparability (1)
- contrast agent (1)
- coronary artery disease (1)
- criteria (1)
- daratumumab (1)
- delineation (1)
- dementia (1)
- depression (1)
- detection rate (1)
- diabetic cardiomyopathy (1)
- diffusion weighted mri (1)
- disease (1)
- dosimetry (1)
- ejection fraction (1)
- endocrinology (1)
- endoradiotherapy (1)
- esophagogastric junction (1)
- evans blue (1)
- experience (1)
- extramedullary hematopoiesis (1)
- fatty acid (1)
- glioblastoma (1)
- glioma (1)
- glomerular filtration rate (1)
- guidelines (1)
- head and neck cancer (1)
- heart failure with mid-range ejection fraction (1)
- heart-to-mediastinum ratio (1)
- hiPSC-CM (1)
- high risk (1)
- hyperkalemia (1)
- imaging (1)
- imaging techniques (1)
- immune infiltration (1)
- immunostaining (1)
- improves (1)
- in vivo imaging (1)
- induced pluripotent stem cells (1)
- inflammation (1)
- intraindividual comparison (1)
- involvement (1)
- kidney function (1)
- left-ventricular function (1)
- lesions (1)
- linear conversion (1)
- mRNA (1)
- machine learning (1)
- macrophages (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- malignancies (1)
- management (1)
- medium-sized animals (1)
- metabolic tumor volume (MTV) (1)
- metabolic tumour volume (MTV) (1)
- methionine (1)
- methionine pet (1)
- miRNA (1)
- microenvironment (1)
- microglial cells (1)
- mouse (1)
- multiple system atrophy (1)
- myocardial perfusion imaging (1)
- myocarditis (1)
- nephrology (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- nuclear medicine (1)
- ollimator (1)
- organic cation transporter (1)
- pancreas (1)
- pattern (1)
- peptide receptor (1)
- performance (1)
- peripheral nervous system (1)
- phaeochromocytoma (1)
- phenethylguanidine (1)
- pleural mesothelioma (1)
- positron emission tomography/computed tomography (1)
- positron-emission-tomography (1)
- post-reconstruction filtering (1)
- progression (1)
- prostate-specific membrane antigen (1)
- quality (1)
- quantification (1)
- radiogenomics (1)
- radiotherapy (1)
- radiotracer (1)
- radiotracer kinetics (1)
- rats (1)
- recurrent prostate cancer (1)
- refractory (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- reporting and data system (1)
- reporting and data systems (1)
- risk (1)
- scanner (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skeletal (1)
- skin biopsy (1)
- small animal SPECT (1)
- small-animal imaging (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin (1)
- somatostatin receptor (SSTR) (1)
- somatostatin receptors (1)
- spleen (1)
- split renal function (1)
- standardization (1)
- stem cell therapy (1)
- stem cells (1)
- stem-cell research (1)
- stem-cell transplantation (1)
- stimulation (1)
- storage vesicle turnover (1)
- structure–activity relationships (1)
- total lesion PSMA (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- tracer (1)
- transcriptome (1)
- treatment response (1)
- tumor burden (1)
- tumor heterogeneity (1)
- tumor microenvironment (1)
- unilateral ureteral obstruction (1)
- urology (1)
- vestibular schwannoma (1)
- γ-H2AX (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (74) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (9)
- Johns Hopkins University School of Medicine (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (1)
- Department of Nuclear Medicine, Kanazawa University (1)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (1)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (1)
- Johns Hopkins University, Baltimore, MD, U.S. (1)
- Johns Hopkis School of Medicine (1)
EU-Project number / Contract (GA) number
- 701983 (21)
We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer \(^{68}\)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard \(^{18}\)F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent \(^{18}\)F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. \(^{68}\)Ga-Pentixafor visualized tumor lesions in 10/11 subjects, while \(^{18}\)F-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, \(^{18}\)F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, n = 107; p < 0.001). Semi-quantitative analysis revealed markedly higher 18F-FDG uptake as compared to \(^{68}\)Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUVmax: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUVmean: 7.4 ± 5.4 vs. 3.1 ± 3.2, p < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, p < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard \(^{18}\)F-FDG PET/CT.
The norepinephrine transporter (NET) is a major target for the evaluation of the cardiac sympathetic nerve system in patients with heart failure and Parkinson's disease. It is also used in the therapeutic applications against certain types of neuroendocrine tumors, as exemplified by the clinically used \(^{123/131}\)I-MIBG as theranostic single-photon emission computed tomography (SPECT) agent. With the development of more advanced positron emission tomography (PET) technology, more radiotracers targeting NET have been reported, with superior temporal and spatial resolutions, along with the possibility of functional and kinetic analysis. More recently, fluorine-18-labelled NET tracers have drawn increasing attentions from researchers, due to their longer radiological half-life relative to carbon-11 (110 min vs. 20 min), reduced dependence on on-site cyclotrons, and flexibility in the design of novel tracer structures. In the heart, certain NET tracers provide integral diagnostic information on sympathetic innervation and the nerve status. In the central nervous system, such radiotracers can reveal NET distribution and density in pathological conditions. Most radiotracers targeting cardiac NET-function for the cardiac application consistent of derivatives of either norepinephrine or MIBG with its benzylguanidine core structure, e.g. \(^{11}\)C-HED and \(^{18}\)F-LMI1195. In contrast, all NET tracers used in central nervous system applications are derived from clinically used antidepressants. Lastly, possible applications of NET as selective tracers over organic cation transporters (OCTs) in the kidneys and other organs controlled by sympathetic nervous system will also be discussed.
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.
Utilizing 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT), we performed this pilot study to evaluate the link between cytogenetic/genomic markers and imaging patterns in relapsed/refractory (RR) multiple myeloma (MM). We retrospectively analyzed data of 24 patients with RRMM who were treated at our institution between November 2018 and February 2020. At the last relapse/progression, patients had been treated with a median of three (range 1–10) lines of therapy. Six (25%) patients showed FDG avid extramedullary disease without adjacency to bone. We observed significantly higher maximum standardized uptake values (SUV\(_{max}\)) in patients harboring del(17p) compared with those without del(17p) (p = 0.025). Moreover, a high SUV\(_{max}\) of >15 indicated significantly shortened progression-free survival (PFS) (p = 0.01) and overall survival (OS) (p = 0.0002). One female patient exhibited biallelic TP53 alteration, i.e., deletion and mutation, in whom an extremely high SUV\(_{max}\) of 37.88 was observed. In summary, this pilot study suggested a link between del(17p)/TP53 alteration and high SUV\(_{max}\) on 18F-FDG PET/CT in RRMM patients. Further investigations are highly warranted at this point.
Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy
(2020)
[\(^{18}\)F]fluorodeoxyglucose (FDG) PET and [\(^{123}\)I]metaiodobenzylguanidine (MIBG) scintigraphy may contribute to the differential diagnosis of neurodegenerative parkinsonism. To identify the superior method, we retrospectively evaluated 54 patients with suspected neurodegenerative parkinsonism, who were referred for FDG PET and MIBG scintigraphy. Two investigators visually assessed FDG PET scans using an ordinal 6-step score for disease-specific patterns of Lewy body diseases (LBD) or atypical parkinsonism (APS) and assigned the latter to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome. Regions-of-interest analysis on anterior planar MIBG images served to calculate the heart-to-mediastinum ratio. Movement disorder specialists blinded to imaging results established clinical follow-up diagnosis by means of guideline-derived case vignettes. Clinical follow-up (1.7 +/- 2.3 years) revealed the following diagnoses: n = 19 LBD (n = 17 Parkinson's disease [PD], n = 1 PD dementia, and n = 1 dementia with Lewy bodies), n = 31 APS (n = 28 MSA, n = 3 PSP), n = 3 non-neurodegenerative parkinsonism; n = 1 patient could not be diagnosed and was excluded. Receiver operating characteristic analyses for discriminating LBD vs. non-LBD revealed a larger area under the curve for FDG PET than for MIBG scintigraphy at statistical trend level for consensus rating (0.82 vs. 0.69, p = 0.06; significant for investigator #1: 0.83 vs. 0.69, p = 0.04). The analysis of PD vs. MSA showed a similar difference (0.82 vs. 0.69, p = 0.11; rater #1: 0.83 vs. 0.69, p = 0.07). Albeit the notable differences in diagnostic performance did not attain statistical significance, the authors consider this finding clinically relevant and suggest that FDG PET, which also allows for subgrouping of APS, should be preferred.
We aimed to investigate the image quality of the U-SPECT5/CT E-Class a micro single-photon emission computed tomography (SPECT) system with two large stationary detectors for visualization of rat hearts and bones using clinically available \(^{99m}\)Tc-labelled tracers. Sensitivity, spatial resolution, uniformity and contrast-to-noise ratio (CNR) of the small-animal SPECT scanner were investigated in phantom studies using an ultra-high-resolution rat and mouse multi-pinhole collimator (UHR-RM). Point source, hot-rod, and uniform phantoms with \(^{99m}\)Tc-solution were scanned for high-count performance assessment and count levels equal to animal scans, respectively. Reconstruction was performed using the similarity-regulated ordered-subsets expectation maximization (SROSEM) algorithm with Gaussian smoothing. Rats were injected with similar to 100 MBq [\(^{99m}\)TcTc-MIBI or similar to 150 MBq [\(^{99m}\)Tc]Tc-HMDP and received multi-frame micro-SPECT imaging after tracer distribution. Animal scans were reconstructed for three different acquisition times and post-processed with different sized Gaussian filters. Following reconstruction, CNR was calculated and image quality evaluated by three independent readers on a five-point scale from 1="very poor" to 5="very good". Point source sensitivity was 567 cps/MBq and radioactive rods as small as 1.2 mm were resolved with the UHR-RM collimator. Collimator-dependent uniformity was 55.5%. Phantom CNR improved with increasing rod size, filter size and activity concentration. Left ventricle and bone structures were successfully visualized in rat experiments. Image quality was strongly affected by the extent of post-filtering, whereas scan time did not have substantial influence on visual assessment. Good image quality was achieved for resolution range greater than 1.8 mm in bone and 2.8 mm in heart. The recently introduced small animal SPECT system with two stationary detectors and UHR-RM collimator is capable to provide excellent image quality in heart and bone scans in a rat using standardized reconstruction parameters and appropriate post-filtering. However, there are still challenges in achieving maximum system resolution in the sub-millimeter range with in vivo settings under limited injection dose and acquisition time.
Background
Small-animal single-photon emission computed tomography (SPECT) systems with multi-pinhole collimation and large stationary detectors have advantages compared to systems with moving small detectors. These systems benefit from less labour-intensive maintenance and quality control as fewer prone parts are moving, higher accuracy for focused scans and maintaining high resolution with increased sensitivity due to focused pinholes on the field of view. This study aims to investigate the performance of a novel ultra-high-resolution scanner with two-detector configuration (U-SPECT5-E) and to compare its image quality to a conventional micro-SPECT system with three stationary detectors (U-SPECT\(^+\)).
Methods
The new U-SPECT5-E with two stationary detectors was used for acquiring data with \(^{99m}\)Tc-filled point source, hot-rod and uniformity phantoms to analyse sensitivity, spatial resolution, uniformity and contrast-to-noise ratio (CNR). Three dedicated multi-pinhole mouse collimators with 75 pinholes each and 0.25-, 0.60- and 1.00-mm pinholes for extra ultra-high resolution (XUHR-M), general-purpose (GP-M) and ultra-high sensitivity (UHS-M) imaging were examined. For CNR analysis, four different activity ranges representing low- and high-count settings were investigated for all three collimators. The experiments for the performance assessment were repeated with the same GP-M collimator in the three-detector U-SPECT\(^+\) for comparison.
Results
Peak sensitivity was 237 cps/MBq (XUHR-M), 847 cps/MBq (GP-M), 2054 cps/MBq (UHS-M) for U-SPECT5-E and 1710 cps/MBq (GP-M) for U-SPECT\(^+\). In the visually analysed sections of the reconstructed mini Derenzo phantoms, rods as small as 0.35 mm (XUHR-M), 0.50 mm (GP-M) for the two-detector as well as the three-detector SPECT and 0.75 mm (UHS-M) were resolved. Uniformity for maximum resolution recorded 40.7% (XUHR-M), 29.1% (GP-M, U-SPECT5-E), 16.3% (GP-M, U-SPECT\(^+\)) and 23.0% (UHS-M), respectively. UHS-M reached highest CNR values for low-count images; for rods smaller than 0.45 mm, acceptable CNR was only achieved by XUHR-M. GP-M was superior for imaging rods sized from 0.60 to 1.50 mm for intermediate activity concentrations. U-SPECT5-E and U-SPECT+ both provided comparable CNR.
Conclusions
While uniformity and sensitivity are negatively affected by the absence of a third detector, the investigated U-SPECT5-E system with two stationary detectors delivers excellent spatial resolution and CNR comparable to the performance of an established three-detector-setup.
Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of \(^{99m}\)Tc-mercaptoacetyltriglycine (\(^{99m}\)Tc-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq \(^{177}\)Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by \(^{99m}\)Tc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.
Diagnosis of cardiac sarcoidosis is often challenging. Whereas cardiac magnetic resonance imaging (CMR) and positron emission tomography/computed tomography (PET/CT) with \(^{18}\)F-fluorodeoxyglucose (FDG) are most commonly used to evaluate patients, PET/CT using radiolabeled somatostatin receptor (SSTR) ligands for visualization of inflammation might represent a more specific alternative. This study aimed to investigate the feasibility of SSTR–PET/CT for detecting cardiac sarcoidosis in comparison to CMR.
15 patients (6 males, 9 females) with sarcoidosis and suspicion on cardiac involvement underwent SSTR-PET/CT imaging and CMR. Images were visually scored. The AHA 17-segment model of the left myocardium was used for localization and comparison of inflamed myocardium for both imaging modalities. In semi-quantitative analysis, mean (SUV\(_{mean}\)) and maximum standardized uptake values (SUV\(_{max}\)) of affected myocardium were calculated and compared with both remote myocardium and left ventricular (LV) cavity.
SSTR-PET was positive in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET- subjects, one patient with minor involvement (<25% of wall thickness in CMR) was missed by PET. The remaining two CMR+/PET- patients displayed no adverse cardiac events during follow-up.
In the 17-segment model, PET/CT yielded 27 and CMR 29 positive segments. Overall concordance of the 2 modalities was 96.1% (245/255 segments analyzed). SUV\(_{mean}\) and SUV\(_{max}\) in inflamed areas were 2.0±1.2 and 2.6±1.2, respectively. The lesion-to-remote myocardium and lesion-to-LV cavity ratios were 1.8±0.2 and 1.9±0.2 for SUV\(_{mean}\) and 2.0±0.3 and 1.7±0.3 for SUV\(_{max}\), respectively.
Detection of cardiac sarcoidosis by SSTR-PET/CT is feasible. Our data warrant further analysis in larger prospective series.
Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of \(^{68}\)Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All \(^{68}\)Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p < 0.01) and PSMA-derived tumor volume (p < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.